Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$471.85 USD

471.85
1,399,486

+1.77 (0.38%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $471.75 -0.10 (-0.02%) 6:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sreyoshi Mukherjee headshot

3 Stocks to Watch as Bots Take Bigger Strides in US Healthcare

by Sreyoshi Mukherjee

Robotics and mechatronics shape up the U.S. medical industry; three stocks that catch the eye.

    Zacks Equity Research

    Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio

    by Zacks Equity Research

    IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.

      Zacks Equity Research

      Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT

      by Zacks Equity Research

      Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.

        Zacks Equity Research

        Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio

        by Zacks Equity Research

        A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.

          Zacks Equity Research

          Stryker (SYK) to Acquire Invuity, Boost Surgical Portfolio

          by Zacks Equity Research

          Stryker (SYK) on an acquisition spree; latest buyout likely to aid its array of surgical instruments.

            Zacks Equity Research

            Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?

            by Zacks Equity Research

            Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.

              Zacks Equity Research

              Integra Lifesciences Picked for Healogics iSupply Program

              by Zacks Equity Research

              Integra Lifesciences' (IART) selection as a key provider for cellular-based tissue products within Healogics' new iSupply program to boost the top line.

                Zacks Equity Research

                Varian Up on Tie-Up With Kenya's Mediheal Group of Hospitals

                by Zacks Equity Research

                Varian's (VAR) advanced cancer care solution prospects bright in the global market.

                  Zacks Equity Research

                  Here's Why You Should Invest in Surmodics (SRDX) Stock Now

                  by Zacks Equity Research

                  Continuous focus on R&D and a raised guidance for fiscal 2018 make Surmodics (SRDX) a lucrative pick for investors.

                    Zacks Equity Research

                    IDEXX Gains Ground on Solid CAG Business Amid Forex Woes

                    by Zacks Equity Research

                    IDEXX (IDXX) continues to see strong organic growth, driven by solid sales at the CAG business. However, unfavorable currency movement remains a concern.

                      Zacks Equity Research

                      Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake

                      by Zacks Equity Research

                      Abbott (ABT) to see a rise in customer adoption of its DRG therapy following the receipt of new national coverage from Aetna.

                        Zacks Equity Research

                        Here's Why You Should Hold On to Quest Diagnostics (DGX) Now

                        by Zacks Equity Research

                        Tough competitive landscape and reimbursement issues are major deterrents to Quest Diagnostics' (DGX) top line in the near term. The company's focus on promising areas to drive growth is a positive.

                          Zacks Equity Research

                          Boston Scientific to Boost MedSurg Unit Via Augmenix Buyout

                          by Zacks Equity Research

                          Boston Scientific (BSX) continues to adopt organic as well as inorganic means to boost top line.

                            Zacks Equity Research

                            Penumbra Launches Reperfusion Catheters, Boosts Neuro Unit

                            by Zacks Equity Research

                            Penumbra (PEN) adopts initiatives to boost the highest revenue generating Neuro business.

                              Zacks Equity Research

                              Genomic Health Prostate Cancer Business Solid, Cost Woes Stay

                              by Zacks Equity Research

                              Within the prostate cancer space, Genomic Health (GHDX) is seeing increasing private coverage for the Oncotype DX GPS test. Costs and operating expenses continue to rise.

                                Zacks Equity Research

                                Why Intuitive Surgical (ISRG) is a Top Pick for Momentum Investors

                                by Zacks Equity Research

                                Does Intuitive Surgical (ISRG) have what it takes to be a top stock pick for momentum investors? Let's find out.

                                  Zacks Equity Research

                                  Here's Why You Should Invest in athenahealth (ATHN) Now

                                  by Zacks Equity Research

                                  Focus on cloud-based services and a lifted guidance for 2018 make athenahealth (ATHN) an attractive pick.

                                    Zacks Equity Research

                                    Varian's (VAR) ProBeam System Gets Picked by Delray Medical

                                    by Zacks Equity Research

                                    Varian Medical's (VAR) coveted ProBeam platform sees a slew of developments; market prospects solid.

                                      Zacks Equity Research

                                      HealthEquity (HQY) Beats Q2 Earnings & Revenue Estimates

                                      by Zacks Equity Research

                                      Strong HSA Member growth boosts HealthEquity's (HQY) results in Q2. A strong guidance raises investors??? optimism.

                                        Zacks Equity Research

                                        Here's Why You Should Hold on to Abiomed (ABMD) for Now

                                        by Zacks Equity Research

                                        Abiomed's (ABMD) margin continues to remain pressed; an upbeat view for fiscal 2019 encourages.

                                          Zacks Equity Research

                                          Amedisys Ties Up With Medalogix to Boost Home Health Unit

                                          by Zacks Equity Research

                                          Amedisys (AMED) pursues deals to boost Home Health business.

                                            Zacks Equity Research

                                            Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3

                                            by Zacks Equity Research

                                            Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.

                                              Zacks Equity Research

                                              Here's Why You Should Invest in Veeva (VEEV) Stock Right Now

                                              by Zacks Equity Research

                                              Strong fundamentals and a solid Q2 aid Veeva (VEEV).

                                                Zacks Equity Research

                                                Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost

                                                by Zacks Equity Research

                                                Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.

                                                  Zacks Equity Research

                                                  Here's Why You Should Invest in Phibro (PAHC) Right Now

                                                  by Zacks Equity Research

                                                  Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.